NCT00193323

Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients

A Randomized Phase III Comparison of Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Elderly or Poor Performance Status Patients With Advanced Non-Small Cell Lung Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 346 (planned)
• Sponsor: SCRI Development Innovations, LLC · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

In this randomized trial, we attempt to further define optimal palliative chemotherapy for elderly patients with advanced non-small cell lung cancer by comparing single agent treatment with weekly docetaxel versus combination therapy with weekly docetaxel plus gemcitabine.

Detailed description

Upon determination of eligibility, patients will be randomly assigned to one of two treatment arms: Docetaxel Docetaxel + Gemcitabine For ever 2 patients treated, 1 will receive treatment A (docetaxel) and 1 will receive treatment B (Docetaxel + Gemcitabine). The study is not blinded so both the patient and the doctor will know which treatment has been assigned.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
DRUG	Docetaxel
DRUG	Gemcitabine

Timeline

• Start date: 2001-08-01
• Primary completion: 2006-05-01
• Completion: 2009-01-01
• First posted: 2005-09-19
• Last updated: 2010-06-28

Locations

1 site across 1 country: United States